On July 1, 2026, the Drug Enforcement Administration (DEA) filed three separate Notices of Intent with the Federal Register, all published five days later. Together they set in motion the most consequential attempt yet to place 7-hydroxymitragynine, the kratom alkaloid known as 7-OH, into Schedule I of the Controlled Substances Act, the same highly restrictive category as heroin and LSD. Bundled into the same regulatory action, almost as an afterthought, is a synthetic opioid with no connection to kratom at all: SR-17018, a compound several researchers consider one of the most promising leads in a decade of trying to build a safer opioid.
The fight over these notices has split the kratom advocacy world into two camps that were, as recently as 2016, on the same side of an earlier scheduling attempt. It has also revived a set of older arguments about how American drug law actually gets made: who research access serves, who gets protected from prohibition and who doesn’t, and whether banning a specific molecule ever reduces the harm regulators say they’re worried about.
Inside the DEA’s 7-OH Ban: Three Notices, One Threshold
The first notice proposes temporarily scheduling 7-OH above a specific threshold: any kratom leaf material testing above 0.05 percent 7-OH by dry weight, or any processed article, extract, or synthesized product containing more than 0.05 percent 7-OH or over 1 milligram per unit. The second targets three related compounds outright, with no threshold: mitragynine pseudoindoxyl (a rearranged form of kratom’s main alkaloid), and two synthesized derivatives called MGM-15 and MGM-16. The third groups SR-17018 with a handful of other investigational opioid compounds, none derived from kratom.
Schedule I is reserved for substances the government judges to have a high potential for abuse and no currently accepted medical use. It’s also the schedule that makes research hardest: a special DEA registration, facility inspections, and separately approved protocols stand between a scientist and the compound, on top of funding restrictions that apply until a substantial body of evidence already exists, which is a deliberately difficult bar to clear for a substance that…it’s illegal…to gather evidence on.
Temporary scheduling under this part of the Controlled Substances Act does not legally require a public comment period. That’s what makes the parallel move notable: HHS opened a Request for Information docket specifically on the proposed 7-OH threshold, taking comments through July 31. There is no equivalent open comment period for the mitragynine pseudoindoxyl/MGM notice or for the SR-17018 notice, which is part of why groups like Students for Sensible Drug Policy have shifted to direct outreach to Congress, DEA, and FDA on those two fronts instead. Who knows if they’ll actually listen to what people are saying about this drug, but the opening of the comment period is a noteworthy move.
The orders themselves took effect roughly a month after publication, putting the SR-17018 cluster on track for late July and the 7-OH and mitragynine-derivative orders for early August. If finalized, both would run for two years, with a possible one-year extension while a permanent scheduling review proceeds.
H2: What Is 7-OH? The Kratom Alkaloid, Explained
Kratom leaf, from the tree Mitragyna speciosa, contains dozens of alkaloids. The dominant one is mitragynine, which behaves oddly at the mu-opioid receptor: it binds, but weakly, and mostly acts as a partial agonist without triggering the beta-arrestin-2 signaling pathway associated with classic opioid side effects like respiratory depression. 7-OH is a minor alkaloid by comparison, present in unprocessed leaf in amounts small enough that the DEA’s own proposed 0.05 percent threshold is meant to exclude ordinary kratom leaf powder entirely. But 7-OH behaves very differently at the receptor than its parent compound: in vitro studies put its binding affinity roughly nine times higher than mitragynine’s, and several assays have found it three to thirteen times more potent than morphine, depending on the model used. It’s a potent drug, without a doubt.
Drug manufacturers did what drug manufacturers do as soon as 7-OH started gaining popularity: they figured out how to concentrate it, and they marketed it in the most staggeringly reckless manner imaginable. Products marketed as “enhanced” tablets, shots, and gummies started showing up on shelves around 2023, and the media machine took off. Scare stories started popping up about this new “gas station drug”. Critics and fear-mongers called it the next great evil. Advocates called it God’s gift to mankind, a perfectly banal drug with no side effects. The truth, as it always does, failed to conform to either of these extremes. As is also almost always the case when it comes to these complex issues, it’s impossible to assign blame to a single actor or agenda here. Critics of prohibition argue that banning a compound does not eliminate demand. Instead, they contend it often pushes users toward novel alternatives or back to street opioids. Overdose numbers are, mercifully, down, and one can’t help but wonder if the proliferation of 7-OH might have something to do with that.
Many researchers argue that 7-OH’s biased signaling profile could translate into a meaningfully lower risk of respiratory depression while maintaining comparable pain relief. That potential safety profile has become a central argument among proponents who see 7-OH as a harm reduction tool. Critics of efforts to place the compound in Schedule I argue that doing so could limit access to what they view as a potentially safer alternative for people who use opioids, particularly amid the ongoing opioid overdose crisis.
The 2016 Kratom Ban Fight — and How 7-OH Got Here
This isn’t the first time 7-OH has faced this exact fate. In August 2016, the DEA announced intent to place kratom, mitragynine and 7-OH included, into Schedule I. What followed was an unusual and largely successful mobilization: the American Kratom Association raised roughly five times its normal annual budget in a single month, and lobbyist Mac Haddow assembled a congressional coalition wide enough to include both Orrin Hatch and Bernie Sanders on a letter opposing the ban. The DEA withdrew its notice. Hamilton Morris, the documentary filmmaker and science journalist whose long-running study of psychoactive drug chemistry has tracked kratom’s regulatory fights for years, described during a recent livestream that reversal as one of the more inspiring examples he’s seen of an organized user base and industry successfully pushing back against a scheduling decision that, in his view, was never grounded in particularly strong evidence.
The DEA’s current filings lean on a different, more recent evidence base. Its notice cites FAERS adverse-event reports involving 7-OH climbing from single digits in 2023 and 2024 to 66 in 2025, with 17 more logged by February 2026, most involving dependence or withdrawal rather than acute overdose. Separately, DEA toxicology testing identified mitragynine pseudoindoxyl, not 7-OH itself, in 31 overdose cases between February 2025 and February 2026, 25 of them fatal, though the notice doesn’t specify how many involved other substances as well. Poison control centers logged 1,690 kratom-related exposure calls in the first seven months of 2025 alone. Those numbers are real, and they’re also small relative to the scale of the American opioid crisis, a gap that critics of the scheduling push keep pointing back to: whatever risk 7-OH carries, it isn’t showing up in the data as one of the country’s larger public health threats, and prohibition has a documented history of being pursued regardless of that fact.
Why Kratom Advocates Turned Against 7-OH
The most striking part of the current fight is who’s on which side. The American Kratom Association and the Global Kratom Coalition, both of which spent 2016 fighting to keep kratom legal, now support scheduling concentrated and synthesized 7-OH, while drawing a hard line around natural leaf. The American Medical Association adopted a policy in June 2026 calling for a ban on 7-OH sale, distribution, and marketing, citing candy-style packaging and gas station availability as drivers of youth exposure. Haddow’s public framing has been blunt: chemically manipulated 7-OH opioids, in his view, simply aren’t kratom, and defending them puts the entire plant’s legal status at risk.
The Money Behind the 7-OH Ban
At the center is Jerry W. “J.W.” Ross, the founder of Botanic Tonics and the man who created Feel Free. Ross is no longer the company’s CEO, but he remains its chairman, and the Global Kratom Coalition’s federal tax filing lists him as the organization’s president. The GKC is not operating on the budget of a grassroots consumer group: in 2024 it reported $3.43 million in contributions and $3.26 million in expenses, including a $575,000 grant to the University of Florida Foundation for kratom research. In California, the coalition spent $15,000 lobbying for AB 2365 and made $41,900 in political contributions to the bill’s author, Assembly member Matt Haney, and Attorney General Rob Bonta, who supported it. Botanic Tonics separately reported spending $90,000 on lobbying during the legislative session, including $30,000 during the period when it was advocating for AB 2365. The bill would have banned synthesized kratom alkaloids and imposed a strict ceiling on 7-OH, restricting the new category competing with Feel Free while largely preserving the leaf-kratom market in which Ross had built his fortune. That does not prove that every safety concern was insincere, but it makes the coalition’s public-health campaign impossible to separate cleanly from its members’ commercial interests.
The campaign soon expanded far beyond one statehouse. Federal lobbying records show that the GKC paid BGR Government Affairs $120,000 in 2025 to advocate on “FDA enforcement and DEA scheduling.” A subsequent New York Times investigation reported that Ross’s allies created an opaque group called Stop Gas Station Heroin, which paid a well-connected lobbying firm at least $600,000 to press congressional offices and Kennedy’s health department for tougher enforcement against synthetic products. After the Justice Department abandoned its case against Botanic Tonics, Ross donated $443,000 to the Republican National Committee in connection with a dinner headlined by Vice President JD Vance and obtained a private meeting in which, according to people briefed on it, he urged the administration and DEA to clamp down on 7-OH.
Over the following two months, Botanic Tonics contributed another $1 million to the Kennedy-aligned MAHA PAC—roughly 44 percent of everything the PAC had raised since the beginning of 2025. None of this establishes an explicit quid pro quo. It does, however, explain why so many former allies have stopped viewing the split as an abstract disagreement about pharmacology. One side has been funding research, lobbyists, political committees and direct access to government while asking regulators to eliminate a competing product category and leave its own standing.
The Case for Regulating 7-OH Instead
On the other side sit newer groups built specifically around 7-OH: the Los Angeles-based 7-HOPE Alliance and the Holistic Alternative Recovery Trust, both of which argue for regulation rather than prohibition. Their proposed framework looks a lot like what alcohol or cannabis regulation looks like in most states: a 21-plus age minimum, sales restricted to age-verified retail, current good manufacturing practice standards, lab testing, and a ban on gas station and convenience store sales. What they oppose is Schedule I placement itself, on the grounds that for a meaningful number of users, 7-OH functions as a lower-harm alternative to full opioid agonists or full-blown opioid use, and that criminalizing it will not make that population disappear.
Why the 7-OH Fight Echoes Past Drug Bans
Hamilton Morris offered a helpful metaphor during the above-linked livestream: some members of the Native American Church have, at times, opposed broader peyote decriminalization efforts. Their own religious use is already legally protected, and what worries them is that expanding access outside that framework could jeopardize the narrow protection they fought hard to secure. Something similar may be driving the so-called “legacy” kratom advocates who now support banning 7-OH: a fear that tolerating it, or even just declining to condemn it, could cost the whole plant its hard-won legality.
During the above-linked livestream, Carl Hart, the Columbia University neuroscientist and longtime critic of American drug policy, offered a more structural critique of the same split. He’s traced a pattern running through more than a century of American drug law: opium regulation arriving alongside anti-Chinese sentiment, cocaine restrictions following moral panic about Black Americans, and alcohol prohibition tracking anxieties about Irish and German immigrants. His argument is that scheduling decisions have tended to follow which group of people used a substance rather than any stable measure of its danger, and he’s been outspoken about drug-reform communities that treat their own substance of choice as categorically different from everyone else’s. He’s called out the psychedelic movement directly in this context, pointing to figures like Joe Rogan, who joined President Trump in the Oval Office in April 2026 for an executive order easing research restrictions on ibogaine and related compounds, as an example of advocacy energy that hasn’t extended to kratom or 7-OH users making the same basic argument for bodily autonomy.
SR-17018: The Non-Kratom Opioid Caught in the 7-OH Ban
The DEA’s third notice targets a cluster of investigational opioid compounds that have nothing to do with kratom, chief among them SR-17018 (also called 5,6-dichloro desmethylchlorphine), alongside SR-14968, R-6890, and 5,6-dichloro-brorphine. SR-17018 was developed in academic pain-signaling research as a “G-protein-biased” mu-opioid agonist, part of a broader effort to design opioids that relieve pain without triggering the beta-arrestin-2 pathway tied to respiratory depression and tolerance. It has never been sold as an approved medication. It circulates instead through gray-market research-chemical vendors, and a meaningful number of the people buying it report using it to manage opioid withdrawal with side effects they describe as far more tolerable than methadone or buprenorphine.
That gray-market status is exactly what put it on the DEA’s radar, and it’s also what makes the scheduling notice controversial among researchers who study biased agonism as a strategy for building safer opioids generally. Groups including Students for Sensible Drug Policy have pointed out that the compound is naloxone-reversible in preclinical work and hasn’t been tied to confirmed overdose deaths, and they’re asking DEA, FDA, and Congress for compound-specific review rather than blanket Schedule I placement bundled with less-studied analogs. Because there’s no open comment docket for this notice the way there is for 7-OH, that advocacy is running through direct petitions and legislative outreach rather than a formal public record. The order is on track to take effect on or after July 31, 2026, giving the research community roughly the same thirty-day window everyone else in this fight has been working against.
How the 7-OH Ban Could Play Out
One detail buried in the DEA’s own mitragynine-derivative notice undercuts the case for scheduling as a solution more than it supports it. The agency has found no evidence that MGM-16 is currently being sold to consumers. It’s including MGM-16 in the ban anyway, because it identified a vendor listing the compound for future sale and concluded that scheduling MGM-15 without also scheduling MGM-16 would hand manufacturers an obvious workaround. That’s a fairly direct acknowledgment of what drug policy researchers sometimes call the iron law of prohibition: restricting a substance doesn’t reduce the underlying demand, it just reroutes that demand toward whatever chemical variant hasn’t been banned yet, and there’s no guarantee the replacement is safer than what it replaced. Synthetic cannabinoids followed exactly this pattern after early bans on specific compounds; the market didn’t shrink, it diversified into dozens of analogs with far less safety data behind them than the substances they replaced.
That dynamic is already visible in how states have responded differently to the same underlying question. Kansas signed HB 2365 on April 10, 2026, taking effect July 1, which reclassifies both kratom and 7-OH as Schedule I under state law and makes possession a felony. Florida’s attorney general issued an emergency rule in June placing concentrated 7-OH into Schedule I at the state level, building on a rule from the previous year. Rhode Island took the opposite path: after banning kratom outright, the state reversed course and implemented a regulatory framework instead, effective April 2026, closer to what 7-HOPE Alliance and HART have been proposing nationally. Whether that model holds up better than prohibition in practice is still an open, empirical question, but it is at least a live comparison case rather than a hypothetical one.
Where the 7-OH Ban Stands Now
The public comment window on the 7-OH threshold closed on July 31. The SR-17018 order took effect around the same date, and the 7-OH and mitragynine-derivative orders shortly after. If the temporary orders go into force as filed, all three sets of compounds will carry Schedule I criminal penalties for two years while a permanent scheduling process plays out behind them, and researchers hoping to study any of them, from the unpublished chemistry involved in converting kratom’s alkaloids into related compounds to the withdrawal-management potential SR-17018’s users report anecdotally, will be doing so under the same registration and funding barriers that have slowed research on cannabis and psychedelics for decades.
It’s a question people like Morris keep asking, and one regulators rarely ask out loud: why has the reported harm from something with this much mu-opioid receptor activity stayed this low, rather than how dangerous the compound might be in a worst-case scenario nobody has actually documented. It’s a real pharmacological question, worth taking seriously on its own terms, and Schedule I placement makes it considerably harder to answer.